Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLC

Karen L. Reckamp, MD, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Learn more about the combination of cabozantinib and erlotinib for NSCLC > >

Articles in this issue

about 12 years ago

Article

Angiogenesis Biomarkers Show Potential for Predicting PFS and OS in NSCLC

about 12 years ago

Article

Tumor Growth Reduced With Cabozantinib Plus Erlotinib in EGFR-Positive NSCLC

about 12 years ago

Article

Update on Next-Generation Therapies for NSCLC

about 12 years ago

Article

Adverse Events Associated With CO-1686

about 12 years ago

Article

<em>RICTOR</em> Amplification in Lung Cancer

about 12 years ago

Article

Peer Discussion on Maintenance Therapy in NSCLC

about 12 years ago

Article

Trials of Anti-PD-L1 in NSCLC Are Well Under Way

Stay up to date on practice-changing data in community practice.

Related to this article

October 20th, 2026

Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC

Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

October 14th, 2026

Insurance Hurdles Complicate Febrile Neutropenia Prevention in ES-SCLC

During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.